Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
“All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.
- “All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.
- Data from the 12 patients, a subset of these 33 CAR T naïve patients, who received the regimen being utilized in ongoing Phase 2 trials was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
- This study compared expansion kinetics among 11 allogeneic CAR T recipients treated with investigational ALLO-501A in the ALPHA2 trial.
- Results of this study could help define strategies to improve allogeneic CAR T expansion, persistence, and efficacy.